Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice

被引:4
|
作者
Ish-Shalom, Sophia [1 ]
Dumitrache, Constantin [2 ]
El-Husseini, Timour Fikry [3 ]
Hussein, Azza [4 ]
Barker, Clare [5 ]
Pavo, Imre [6 ]
机构
[1] Technion Fac Med, Bone & Mineral Metab Unit, Haifa, Israel
[2] CI Parhon Inst Endocrinol, Bucharest, Romania
[3] Ain Shams Univ, Fac Med, Dept Orthoped Surg, Cairo, Egypt
[4] Ain Shams Univ, Fac Med, Dept Rheumatol, Cairo, Egypt
[5] Lilly Res Labs UK, Surrey, England
[6] Lilly Reg Operat Vienna, Dept Med, Vienna, Austria
关键词
QUALITY-OF-LIFE; RADIOGRAPHIC VERTEBRAL FRACTURE; BONE-MINERAL DENSITY; BACK-PAIN; PARATHYROID-HORMONE; OLDER WOMEN; DISABILITY; DEFORMITIES; PREVALENT; RISK;
D O I
10.1185/03007995.2010.540007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To observe and compare back pain and health-related quality of life (HRQoL) in postmenopausal women with a prior unsatisfactory response to antiresorptive therapy, treated with teriparatide (TPTD) or alternative treatments in normal clinical practice. Prospective, observational, multicentre, 24-month study of postmenopausal women with osteoporosis. A back pain and HRQoL questionnaire (European Quality of Life Questionnaire, EQ-5D) including visual analogue scale (VAS) was completed at each visit. A total of 153 patients were enrolled, 105 patients started TPTD treatment during the study (TPTD cohort) and 48 patients did not take TPTD treatment at any time during the study (non-TPTD cohort). Four patients did not meet the inclusion criteria for the study. Of the patients in the non-TPTD cohort, 31 (68.9%) took antiresorptives during the study. The patients selected by the investigator for teriparatide treatment were distinctly different from those not selected. At baseline, the mean back pain VAS was greater in the TPTD than the non-TPTD cohort, 64 mm and 42 mm, respectively (p < 0.001). During the study, compared with baseline, the mean back pain VAS decreased in the TPTD cohort at all visits (p < 0.001). In the non-TPTD cohort, a transitory decrease in the mean after 12 months was observed (-10 mm, p = 0.023) only. After 24 months, the mean back pain VAS improved in the TPTD cohort (-36 mm, p < 0.001) while no change was observed in the non-TPTD cohort (-4 mm, p = 0.467). At baseline, the mean EQ-VAS was lower in the TPTD than in the non-TPTD cohort, 40.8 and 55.2, respectively (p < 0.001). After 24 months, EQ-VAS improved in both cohorts (TPTD 34, p < 0.001 and non-TPTD 9, p = 0.026). TPTD-treated patients had more back pain and lower HRQoL at baseline. In the TPTD cohort the mean value was consistently and significantly improved in back pain and quality of life. In the non-TPTD cohort, the mean improvement in back pain and QoL was inconsistent possibly due to the initially higher QoL and lower back pain leaving less room for improvement. These results should be interpreted in the context of limitations related to a non-randomised observational study.
引用
收藏
页码:343 / 353
页数:11
相关论文
共 50 条
  • [31] Comparison of the effects of teriparatide and calcitonin in the treatment of postmenopausal Chinese women with osteoporosis
    Blair, J. M.
    Dai, K. R.
    Chen, D. C.
    Zhang, Z. L.
    Zhang, K. Q.
    Wang, B. Q.
    He, L.
    Liu, B.
    Xu, H. Z.
    Hu, Y. L.
    Cao, Y. P.
    Thiebaud, D.
    Yu, M.
    Luo, T. H.
    BONE, 2009, 44 : S74 - S74
  • [32] Differential effects of teriparatide and alendronate on bone parameters in postmenopausal women with osteoporosis
    McClung, MR
    Martin, JS
    Meunier, PJ
    Miller, PD
    Haddock, L
    Bandeira, F
    Szejnfled, V
    Donley, DW
    Eriksen, EF
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S5 - S5
  • [33] Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis
    Gallagher, J. C.
    Rosen, C. J.
    Chen, P.
    Misurski, D. A.
    Marcus, R.
    BONE, 2006, 39 (06) : 1268 - 1275
  • [34] Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis
    Gosset Anna
    Farcy Anne-Lise
    Dufond Clémence
    Pouillès Jean-Michel
    Trémollieres Florence
    Journal of Bone and Mineral Metabolism, 2023, 41 : 278 - 285
  • [35] Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis
    Leder, Benjamin Z.
    Neer, Robert M.
    Wyland, Jason J.
    Lee, Hang W.
    Burnett-Bowie, Sherri-Ann M.
    Finkelstein, Joel S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (08): : 2915 - 2921
  • [36] Profile of teriparatide in the management of postmenopausal osteoporosis
    Sikon, Andrea
    Batur, Pelin
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2010, 2 : 37 - 44
  • [37] ZOLEDRONATE AFTER TERIPARATIDE IN POSTMENOPAUSAL OSTEOPOROSIS
    Ryan, P.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S286 - S286
  • [38] Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
    Chen, Peiqi
    Miller, Paul D.
    Delmas, Pierre D.
    Misurski, Derek A.
    Krege, John H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (11) : 1785 - 1790
  • [39] Zoledronate after teriparatide in postmenopausal osteoporosis
    Ryan, P. J.
    BONE, 2009, 44 (02) : S439 - S440
  • [40] Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: A randomized, controlled trial
    Anastasilakis, A. D.
    Goulis, D. G.
    Polyzos, S. A.
    Gerou, S.
    Koukoulis, G.
    Kita, M.
    Avramidis, A.
    HORMONE AND METABOLIC RESEARCH, 2008, 40 (04) : 281 - 285